TherapeuticsMD (TXMD) Equity Average (2011 - 2026)

TherapeuticsMD has reported Equity Average for 15 years, with the latest figure at $26.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average changed 0.48% year-over-year to $26.9 million; the trailing twelve-month figure through Mar 2026 stood at $26.9 million (changed 0.48% YoY), and the FY2025 full-year result was $27.1 million, down 4.26% from the prior year.
• Equity Average for Q1 2026 stood at $26.9 million, down from $27.2 million in the prior quarter.
• The five-year high for Equity Average was $33.6 million in Q1 2023, with the low at -$117.1 million in Q1 2022.
• Historically, Equity Average has averaged $7.4 million across 5 years, with a median of $27.2 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average sank 184.61% — and 2023, when it soared 536.77%.
• TherapeuticsMD's Equity Average stood at -$6.6 million in 2022, then soared by 536.77% to $28.7 million in 2023, then dropped by 5.01% to $27.2 million in 2024, then retreated by 0.26% to $27.2 million in 2025, then declined by 0.87% to $26.9 million in 2026.
• The last three Equity Average figures came in at $26.9 million (Q1 2026), $27.2 million (Q4 2025), and $27.4 million (Q3 2025), per Business Quant data.